


1
FIG.



BEST AVAILABLE COPY

2/13




FIG. 2A

BEST AVAILABLE COPY

3/3




FIG.2B

4/13




FIG. 3A




FIG. 3B

BEST AVAILABLE COPY

5/13




FIG. 4A



FIG. 4B

6/13

Non-treated



Doxorubicin-treated tumors




FIG. 5C





FIG. 5A

FIG. 5B

BEST AVAILABLE COPY

7/13



6
FIG

BEST AVAILABLE COPY

8/13

	<i>Control</i>	<i>Doxo (2x20 mg/kg)</i>
Tumor/ Kidney	0.86	0.59
Tumor/ Heart	1.07	5.69
Tumor/ Liver	0.88	4.68
Tumor/ Muscle	1.61	8.66
Tumor/ Fast tissue	6.60	5.20
Tumor/ Spleen	2.42	3.86
Tumor/ Lung	1.07	2.52
Tumor/ Blood	1.43	3.50
Tumor/Small intestine	1.18	2.26
Tumor	0.07	1.28

FIG. 7

9/13




FIG. 8B




FIG. 8A

10/13




FIG. 9B





FIG. 9A


BEST AVAILABLE COPY

11/13



Ischemic kidney

FIG. 10A



Contralateral side kidney

FIG. 10B

BEST AVAILABLE COPY

12/13




FIG. 11

BEST AVAILABLE COPY

13/13




FIG. 12